1999
DOI: 10.1097/00002030-199904160-00020
|View full text |Cite
|
Sign up to set email alerts
|

Lipodystrophy in patients naive to HIV protease inhibitors

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
79
2
19

Year Published

2002
2002
2008
2008

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 175 publications
(101 citation statements)
references
References 7 publications
1
79
2
19
Order By: Relevance
“…In the HAART era, several studies have shown higher total cholesterol, LDL-C and triglyceride levels associated with PI use [6][7][8]. However, consistent with other investigators' findings of increased lipid levels even in patients on non-PI regimens, we found that non-PI HAART was associated with elevated levels of atherogenic lipoproteins similar to those seen with PI-based HAART [9,10].…”
Section: Discussionsupporting
confidence: 90%
“…In the HAART era, several studies have shown higher total cholesterol, LDL-C and triglyceride levels associated with PI use [6][7][8]. However, consistent with other investigators' findings of increased lipid levels even in patients on non-PI regimens, we found that non-PI HAART was associated with elevated levels of atherogenic lipoproteins similar to those seen with PI-based HAART [9,10].…”
Section: Discussionsupporting
confidence: 90%
“…Similar to other congenital forms of lipodystrophies, HIV lipodystrophy has been shown to be associated with dyslipidemia and insulin resistance (1,3,6). These metabolic alterations are probably, at least in part, secondary to fat redistribution but could also result from drug toxicity (4,7) and can be influenced by individual susceptibility; the role of the virus itself has also been suggested (8). Protease inhibitors (PIs) have been reported to favor insulinresistance and hypertriglyceridemia (9), but the prevalence and severity of altered fat distribution are increased in patients treated with both PIs and nucleoside reverse-transcriptase inhibitor (NRTI) (10).…”
mentioning
confidence: 96%
“…Após cinco anos de seguimento de pacientes HIV positivos, em terapia com IP verificou-se uma incidência cumulativa de 20% de casos de hipercolesterolemia e hipertrigliceridemia. Outro estudo 19 demonstrou que um grupo de pacientes que nunca recebeu IP, e que estava em tratamento com inibidores de transcriptase reversa análogos de nucleosídeo, apresentou níveis elevados de triglicerídeos, sugerindo a existência de outros fatores 11 .…”
Section: Alterações Dos Lipídeosunclassified